header advert
Results 1 - 3 of 3
Results per page:
Orthopaedic Proceedings
Vol. 100-B, Issue SUPP_9 | Pages 28 - 28
1 May 2018
Wilkinson J MacInnes S Hatzikotoulas K Fenstad A Shah K Southam L Tachmazidou I Hallan G Dale H Panoutsopoulou K Furnes O Zeggini E
Full Access

Introduction

Periprosthetic osteolysis resulting in aseptic loosening is a leading cause for total hip arthroplasty (THA) failure. Individuals vary in their susceptibility to osteolysis, and it is thought that heritable factors contribute to this variation. We conducted two genome-wide association studies to identify genetic risk loci associated with osteolysis and genetic risk loci associated with time to prosthesis failure due to osteolysis.

Patients/Materials & Methods

The Norway cohort comprised 2,624 subjects after THA recruited from the Norwegian Arthroplasty Registry, 779 with revision surgery for osteolysis. The UK cohort comprised 890 subjects recruited from hospitals in the north of England, 317 with radiographic evidence or revision surgery for osteolysis. All subjects had received a fully cemented or hybrid THA using small-diameter metal or ceramic-on-conventional polyethylene bearing. Osteolysis susceptibility case-control analyses and quantitative trait analyses for time to prosthesis failure were undertaken after genome-wide genotyping. Finally, a meta-analysis of the discovery datasets was undertaken.


Orthopaedic Proceedings
Vol. 97-B, Issue SUPP_12 | Pages 11 - 11
1 Nov 2015
MacInnes S Wilkinson J
Full Access

Introduction

Aseptic loosening, the clinical endpoint of osteolysis, remains the leading cause of total hip arthroplasty (THA) failure, and is caused by a host response to wear debris that varies between individuals. Although several candidate gene studies have identified loci associated with osteolysis susceptibility, there have been no systematic studies at genome-wide level. We aimed to identify risk loci associated with osteolysis by conducting a genome-wide association study.

Methods

3,706 Caucasian European patients following THA were studied. The discovery cohort comprising 894 patients (317 with osteolysis) were genotyped using the Illumina-610 beadchip followed by 1000 Genome-based imputation covering 10 million single nucleotide polymorphisms (SNPs). Phenotypes were transformed to normality where required, regressed on important covariates and z-standardised. Following quality control, osteolysis case-control analysis and a quantitative trait association analysis for time to prosthesis failure were undertaken. Index SNPs p<9×10−4 were taken forward for replication in a second cohort comprising 2,812 subjects (834 osteolysis cases) recruited from the Norwegian arthroplasty registry. Genotyping was undertaken using Sequenom MassARRAY iPLEX Gold assay and association analyses undertaken using logistic and linear regression. Summary statistics were combined in a fixed-effects meta-analysis framework.


Orthopaedic Proceedings
Vol. 94-B, Issue SUPP_XXXVI | Pages 71 - 71
1 Aug 2012
Thiagarajah S MacInnes S Yang L Wilkinson J
Full Access

Introduction

Subtle variations in hip morphology associate with risk of hip osteoarthritis (OA). However, validated accurate methods to quantitate hip morphology using plain radiography are lacking. We have developed a Matlab-based software-tool (SHIPs) that measures 19 OA-associated morphological-parameters of the hip using a PACS pelvic radiograph. In this study we evaluated the accuracy and repeatability of the method.

Methods

Software accuracy was assessed by firstly measuring the linear ratio of 2 fixed distances and several angles against a gold-standard test radiograph, and secondly by repeated measurements on a simulated AP radiograph of the pelvis (reformatted from CT-data) that was digitally rotated about 3-axes to determine the error associated with pelvic mal-positioning. Repeatability was assessed using 30-AP Pelvic radiographs analysed twice (intra-observer), by 2 readers (inter-observer), and finally, using 2 pelvic radiographs taken in 23 subjects (n=46 radiographs) taken same day after re-positioning (short-term clinical-practice variability), and was expressed as coefficient of variation (CV%).